Housed within the Target Discovery Institute, the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems.
Why we work on Alzheimer’s disease
Loading Video...
The burden caused by Alzheimer’s disease and other dementias represents one of the biggest problems for our healthcare systems. The last medicine was approved in 2002 and today we only have symptomatic treatments. ARUK-ODDI brings together chemists, biologist, psychiatrists and neuroscientists, many of them with pharmaceutical background, aiming to accelerate the discovery of novel and effective treatments.
Series:
People:
Oxford Unit:
More in this Series...
Translational and Clinical Medicine is the ongoing effort to bring basic science from the bench to the patient, as well as to elucidate safety and effectiveness of the medicines on which we depend. The NDM podcasts on translational and clinical medicine detail our work in this wide-ranging field, from the identification and design of new medicines to clinical trials and trial design and regulation.
Subscribe
Download Media
- Video (106.71 MB)